



## **Scrapie prions: an etiologic agent of sCJD in human?**

Caroline C. Lacroux, Juan Mariá Torres, Hervé H. Cassard, Jean-Yves Douet, Sylvie L. Benestad, Frédéric F. Lantier, Séverine S. Lugan, Isabelle Lantier, Pierrette P. Costes, Naima N. Aron, et al.

### **► To cite this version:**

Caroline C. Lacroux, Juan Mariá Torres, Hervé H. Cassard, Jean-Yves Douet, Sylvie L. Benestad, et al.. Scrapie prions: an etiologic agent of sCJD in human?. International Prion Congress 2014, May 2014, Trieste, Italy. 10.4161/pri.29367 . hal-02741564

**HAL Id: hal-02741564**

**<https://hal.inrae.fr/hal-02741564>**

Submitted on 3 Jun 2020

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

This article was downloaded by: [138.102.135.242]

On: 12 March 2015, At: 02:03

Publisher: Taylor & Francis

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



## Prion

Publication details, including instructions for authors and subscription information:

<http://www.tandfonline.com/loi/kprn20>

## Invited Speakers

Published online: 01 Apr 2014.



[Click for updates](#)

To cite this article: (2014) Invited Speakers, Prion, 8:sup1, 3-11, DOI: [10.4161/pri.29367](https://doi.org/10.4161/pri.29367)

To link to this article: <http://dx.doi.org/10.4161/pri.29367>

PLEASE SCROLL DOWN FOR ARTICLE

Taylor & Francis makes every effort to ensure the accuracy of all the information (the "Content") contained in the publications on our platform. Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Versions of published Taylor & Francis and Routledge Open articles and Taylor & Francis and Routledge Open Select articles posted to institutional or subject repositories or any other third-party website are without warranty from Taylor & Francis of any kind, either expressed or implied, including, but not limited to, warranties of merchantability, fitness for a particular purpose, or non-infringement. Any opinions and views expressed in this article are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor & Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content.

This article may be used for research, teaching, and private study purposes. Terms & Conditions of access and use can be found at <http://www.tandfonline.com/page/terms-and-conditions>

It is essential that you check the license status of any given Open and Open Select article to confirm conditions of access and use.

## Invited.24: Scrapie prions: an etiologic agent of sCJD in human?

Caroline Lacroux,<sup>1</sup> Juan María Torres,<sup>2</sup> Hervé Cassard,<sup>1</sup>  
Jean Yves Douet,<sup>1</sup> Sylvie L Benestad,<sup>3</sup> Frédéric Lantier,<sup>4</sup>  
Séverine Lugan,<sup>1</sup> Isabelle Lantier,<sup>4</sup> Pierrette Costes,<sup>1</sup>  
Naima Aron,<sup>1</sup> Juan-Carlos Espinosa,<sup>2</sup> Vincent Béringue,<sup>5</sup>  
and Olivier Andréoletti<sup>1</sup>

<sup>1</sup>UMR INRA ENVT 1225, Interactions Hôtes Agents Pathogènes, Ecole Nationale Vétérinaire de Toulouse; Toulouse, France; <sup>2</sup>CISA- INIA; Valdeolmos; Madrid, Spain;

<sup>3</sup>National Veterinary Institute; Oslo, Norway; <sup>4</sup>INRA ISP, Centre INRA de Tours; Nouzilly, France; <sup>5</sup>UR892 Virologie et Immunologie Moléculaires Centre de Recherche de Jouy-en-Josas; Jouy-en-Josas, France

**Keywords:** Scrapie, zoonosis, Creutzfeldt Jakob disease

While the Bovine Spongiform Encephalopathy (BSE) is the cause of variant CJD in human, the zoonotic potential of Scrapie prions remains mostly unknown. Some rodent-adapted scrapie isolates were reported to propagate in non-human primates. However, because prions adaptation in rodents can profoundly alter their biological properties and no transmission was observed in chimpanzee inoculated with sheep scrapie, the significance of these results was considered low.

Mice genetically engineered to over-express the human prion protein (tgHu) have emerged as highly relevant models for gauging prions capacity to transmit in human. These models can propagate human prions without apparent transmission barrier and they were largely used to confirm the zoonotic ability of the BSE. Here we show that a panel of sheep scrapie prions transmit in several tgHu mice models with comparable efficacy than cattle BSE. The serial transmission of different scrapie isolates in these mice led to the propagation of prions that are phenotypically identical to those causing sporadic Creutzfeldt Jakob disease in humans.

These results demonstrate that scrapie prions have an intrinsic zoonotic potential and raise new questions about the possible links between animal and human prions.

## Invited.25: Transmissibility of human prion diseases

Pierluigi Gambetti

National Prion Disease Pathology Surveillance Center; Departments of Pathology; Case Western Reserve University; Cleveland, OH USA

For many years the notion has been accepted that human prion diseases can be divided as transmissible and non- (or only partially) transmissible. Commonly listed in the first group were all forms of Creutzfeldt-Jakob disease (CJD), fatal insomnia (FI) and the GSS subtype associated to the P102L mutation harboring CJD-like scrapie prion protein (PrP<sup>Sc</sup>) generally identified as PrP27-30; the second group included subtypes of GSS lacking PrP<sup>Sc</sup> 27-30 and variably protease sensitive prionopathy (VPSP), which also lacks significant amount of PrP27-30.

We have probed transmissibility of VPSP using two sets of Tg mice: 1. Tg mice expressing human cellular PrP (PrP<sup>C</sup>) in amounts ranging x1 to x8 the normal mouse level and harboring methionine or valine at position 129 [Tg(HuPrP<sup>C</sup>129V) and Tg(HuPrP<sup>C</sup>129M)]; 2. Tg mice expressing glycan-free human PrP [Tg(HuPrP129MGlycKO)].

Following inoculations of a total of 12 cases of VPSP of the three genotypes and controls to a total of 170 Tg(HuPrP<sup>C</sup>129V) and Tg(HuPrP<sup>C</sup>129M) mice none of the VPSP-inoculated mice manifested clinical signs; 60% of challenged mice were positive at histopathological examination, on average 655 to 711 days post inoculation (dpi) showing PrP-positive plaques and, occasionally, focal spongiform degeneration in or around the hippocampus; about 34% harbored PrP<sup>Sc</sup> with properties similar to those of VPSP PrP<sup>Sc</sup>. Transmission occurred only when host and inoculum PrP 129 residue matched. Virtually, no prion disease was detected at second passage.

VPSP-129M inoculation to Tg(HuPrP129MGlycKO) caused clinical signs and widespread, severe histopathological changes approximately 380 dpi in virtually all challenged mice. Second passage mice also were affected. Histopathological changes that followed VPSP challenge were comparable to those that followed inoculation with brain homogenates from sCJD subtypes.

These findings suggest that the distinction of transmissible and non-transmissible prion diseases in principle is futile since by virtue of their common mechanism prion diseases are all likely to be proven transmissible when they are exposed to a suitable conversion substrate.

**Acknowledgments.** Supported by NIH Award AG14359, CDC Award UR8/CCU515004 and Charles S. Britton Fund.